NYSE:FMS

Fresenius Medical Care AG & Co. KGaA Competitors

$38.16
+0.56 (+1.49 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$37.76
Now: $38.16
$38.20
50-Day Range
$34.37
MA: $36.13
$37.58
52-Week Range
$33.84
Now: $38.16
$46.55
Volume330,782 shs
Average Volume473,828 shs
Market Capitalization$22.35 billion
P/E Ratio15.14
Dividend Yield1.33%
Beta1.21

Competitors

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Vs. DVA, SHC, PGNY, TVTY, TLMD, and OTRK

Should you be buying FMS stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to Fresenius Medical Care AG & Co. KGaA, including DaVita (DVA), Sotera Health (SHC), Progyny (PGNY), Tivity Health (TVTY), SOC Telemed (TLMD), and Ontrak (OTRK).

DaVita (NYSE:DVA) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

91.7% of DaVita shares are held by institutional investors. Comparatively, 1.6% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 1.0% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares DaVita and Fresenius Medical Care AG & Co. KGaA's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$11.39 billion1.06$810.98 million$5.4020.35
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.14$1.34 billion$2.5315.08

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than DaVita. Fresenius Medical Care AG & Co. KGaA is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for DaVita and Fresenius Medical Care AG & Co. KGaA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DaVita13102.00
Fresenius Medical Care AG & Co. KGaA19702.35

DaVita presently has a consensus target price of $114.60, indicating a potential upside of 4.30%. Fresenius Medical Care AG & Co. KGaA has a consensus target price of $45.00, indicating a potential upside of 17.92%. Given Fresenius Medical Care AG & Co. KGaA's stronger consensus rating and higher probable upside, analysts clearly believe Fresenius Medical Care AG & Co. KGaA is more favorable than DaVita.

Risk & Volatility

DaVita has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500.

Profitability

This table compares DaVita and Fresenius Medical Care AG & Co. KGaA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DaVita7.32%43.99%5.27%
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Sotera Health (NYSE:SHC) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

1.6% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Fresenius Medical Care AG & Co. KGaA and Sotera Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.14$1.34 billion$2.5315.08
Sotera HealthN/AN/AN/AN/AN/A

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Sotera Health.

Analyst Recommendations

This is a summary of recent ratings and price targets for Fresenius Medical Care AG & Co. KGaA and Sotera Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fresenius Medical Care AG & Co. KGaA19702.35
Sotera Health001003.00

Fresenius Medical Care AG & Co. KGaA presently has a consensus price target of $45.00, indicating a potential upside of 17.92%. Sotera Health has a consensus price target of $32.75, indicating a potential upside of 25.48%. Given Sotera Health's stronger consensus rating and higher possible upside, analysts clearly believe Sotera Health is more favorable than Fresenius Medical Care AG & Co. KGaA.

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and Sotera Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%
Sotera HealthN/AN/AN/A

Summary

Fresenius Medical Care AG & Co. KGaA beats Sotera Health on 5 of the 8 factors compared between the two stocks.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and Progyny's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%
Progyny1.03%7.43%5.04%

Insider & Institutional Ownership

1.6% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. Comparatively, 58.5% of Progyny shares are held by institutional investors. 33.3% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Fresenius Medical Care AG & Co. KGaA has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500.

Valuation & Earnings

This table compares Fresenius Medical Care AG & Co. KGaA and Progyny's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.14$1.34 billion$2.5315.08
Progyny$229.68 million18.12$-8,570,000.00$0.11433.91

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Progyny. Fresenius Medical Care AG & Co. KGaA is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Fresenius Medical Care AG & Co. KGaA and Progyny, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fresenius Medical Care AG & Co. KGaA19702.35
Progyny00603.00

Fresenius Medical Care AG & Co. KGaA presently has a consensus price target of $45.00, indicating a potential upside of 17.92%. Progyny has a consensus price target of $38.8333, indicating a potential downside of 18.64%. Given Fresenius Medical Care AG & Co. KGaA's higher possible upside, research analysts clearly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Progyny.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Tivity Health (NASDAQ:TVTY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and Tivity Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%
Tivity Health-47.44%128.43%6.11%

Institutional & Insider Ownership

1.6% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. Comparatively, 91.6% of Tivity Health shares are owned by institutional investors. 11.8% of Tivity Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Fresenius Medical Care AG & Co. KGaA has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Tivity Health has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500.

Valuation and Earnings

This table compares Fresenius Medical Care AG & Co. KGaA and Tivity Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.14$1.34 billion$2.5315.08
Tivity Health$1.13 billion1.01$-286,820,000.00$2.0211.48

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Tivity Health. Tivity Health is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Fresenius Medical Care AG & Co. KGaA and Tivity Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fresenius Medical Care AG & Co. KGaA19702.35
Tivity Health12502.50

Fresenius Medical Care AG & Co. KGaA presently has a consensus price target of $45.00, indicating a potential upside of 17.92%. Tivity Health has a consensus price target of $22.1250, indicating a potential downside of 4.55%. Given Fresenius Medical Care AG & Co. KGaA's higher probable upside, analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Tivity Health.

Summary

Fresenius Medical Care AG & Co. KGaA beats Tivity Health on 8 of the 14 factors compared between the two stocks.

SOC Telemed (NASDAQ:TLMD) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Valuation & Earnings

This table compares SOC Telemed and Fresenius Medical Care AG & Co. KGaA's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SOC TelemedN/AN/A$20,000.00N/AN/A
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.14$1.34 billion$2.5315.08

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than SOC Telemed.

Insider and Institutional Ownership

20.7% of SOC Telemed shares are owned by institutional investors. Comparatively, 1.6% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for SOC Telemed and Fresenius Medical Care AG & Co. KGaA, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SOC Telemed01502.83
Fresenius Medical Care AG & Co. KGaA19702.35

SOC Telemed currently has a consensus target price of $11.40, indicating a potential upside of 68.39%. Fresenius Medical Care AG & Co. KGaA has a consensus target price of $45.00, indicating a potential upside of 17.92%. Given SOC Telemed's stronger consensus rating and higher probable upside, research analysts clearly believe SOC Telemed is more favorable than Fresenius Medical Care AG & Co. KGaA.

Profitability

This table compares SOC Telemed and Fresenius Medical Care AG & Co. KGaA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SOC TelemedN/AN/AN/A
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%

Summary

Fresenius Medical Care AG & Co. KGaA beats SOC Telemed on 6 of the 9 factors compared between the two stocks.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Ontrak (NASDAQ:OTRK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

1.6% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. Comparatively, 27.5% of Ontrak shares are owned by institutional investors. 58.2% of Ontrak shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Fresenius Medical Care AG & Co. KGaA and Ontrak, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fresenius Medical Care AG & Co. KGaA19702.35
Ontrak02302.60

Fresenius Medical Care AG & Co. KGaA currently has a consensus target price of $45.00, indicating a potential upside of 17.92%. Ontrak has a consensus target price of $47.20, indicating a potential upside of 51.19%. Given Ontrak's stronger consensus rating and higher probable upside, analysts clearly believe Ontrak is more favorable than Fresenius Medical Care AG & Co. KGaA.

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and Ontrak's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%
Ontrak-43.10%N/A-58.54%

Valuation and Earnings

This table compares Fresenius Medical Care AG & Co. KGaA and Ontrak's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.14$1.34 billion$2.5315.08
Ontrak$35.10 million15.73$-25,660,000.00($1.15)-27.15

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Ontrak. Ontrak is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Fresenius Medical Care AG & Co. KGaA has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Ontrak has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500.

Summary

Fresenius Medical Care AG & Co. KGaA beats Ontrak on 8 of the 14 factors compared between the two stocks.


Fresenius Medical Care AG & Co. KGaA Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
DaVita logo
DVA
DaVita
1.7$109.88+0.8%$12.02 billion$11.39 billion16.47
Sotera Health logo
SHC
Sotera Health
2.0$26.10+1.0%$7.38 billionN/A0.00
Progyny logo
PGNY
Progyny
1.5$47.73+0.5%$4.16 billion$229.68 million433.91Insider Selling
Tivity Health logo
TVTY
Tivity Health
1.0$23.18+1.6%$1.14 billion$1.13 billion-2.10
SOC Telemed logo
TLMD
SOC Telemed
1.6$6.77+2.2%$606.75 millionN/A0.00
Ontrak logo
OTRK
Ontrak
1.7$31.22+3.4%$552.28 million$35.10 million-18.36Gap Down
Viemed Healthcare logo
VMD
Viemed Healthcare
0.9$10.07+2.1%$394.59 million$80.26 million13.99News Coverage
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
1.5$1.59+10.7%$94.60 millionN/A-2.48News Coverage
Baudax Bio logo
BXRX
Baudax Bio
1.4$1.08+8.3%$75.75 millionN/A-0.31News Coverage
GRNV
GreenVision Acquisition
0.3$10.17+0.1%$73.10 millionN/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.